Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Xenon Pharmaceuticals Inc. (XENE)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues | | | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of goods sold | | | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Gross profit | | | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | | | | 28984.8% | 5755.8% | 298.1% | | 292.0% |
| Research and development | | | | | | | | |
| General and administrative | | | | | | | 764.7% | |
| EBITDA | | | | -28021.2% | -5915.3% | -255.3% | -670.4% | -190.7% |
| Depreciation | | | | 271.2% | 70.0% | 4.3% | 7.2% | 2.6% |
| EBIT | | | | -28292.4% | -5985.3% | -259.6% | -677.6% | -193.3% |
| Pre-tax income | | | | -28588.6% | -5820.5% | -228.9% | -671.1% | -192.6% |
| Income taxes | | | | -444.7% | -7.5% | -4.5% | 13.0% | -2.5% |
| Net income | | | | -28143.9% | -5813.1% | -224.4% | -684.1% | -190.1% |
|